- Home
- STTK vs GECC Comparison
STTK vs GECC Comparison
Compare STTK & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- GECC
- Stock Information
- Founded
- STTK 2016
- GECC 2016
- Country
- STTK United States
- GECC United States
- Employees
- STTK N/A
- GECC N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- GECC Finance: Consumer Services
- Sector
- STTK Health Care
- GECC Finance
- Exchange
- STTK Nasdaq
- GECC Nasdaq
- Market Cap
- STTK 112.6M
- GECC 127.9M
- IPO Year
- STTK 2020
- GECC N/A
- Fundamental
- Price
- STTK $1.98
- GECC $7.51
- Analyst Decision
- STTK Hold
- GECC Strong Buy
- Analyst Count
- STTK 5
- GECC 1
- Target Price
- STTK $3.00
- GECC $11.50
- AVG Volume (30 Days)
- STTK 411.4K
- GECC 301.2K
- Earning Date
- STTK 11-13-2025
- GECC 10-30-2025
- Dividend Yield
- STTK N/A
- GECC 20.70%
- EPS Growth
- STTK N/A
- GECC 29.91
- EPS
- STTK N/A
- GECC 1.58
- Revenue
- STTK $2,997,000.00
- GECC $47,638,000.00
- Revenue This Year
- STTK N/A
- GECC $30.26
- Revenue Next Year
- STTK N/A
- GECC N/A
- P/E Ratio
- STTK N/A
- GECC $4.66
- Revenue Growth
- STTK N/A
- GECC 29.12
- 52 Week Low
- STTK $0.69
- GECC $7.18
- 52 Week High
- STTK $2.71
- GECC $11.46
- Technical
- Relative Strength Index (RSI)
- STTK 48.57
- GECC 24.74
- Support Level
- STTK $1.72
- GECC $7.23
- Resistance Level
- STTK $2.71
- GECC $8.09
- Average True Range (ATR)
- STTK 0.22
- GECC 0.53
- MACD
- STTK -0.09
- GECC -0.06
- Stochastic Oscillator
- STTK 25.05
- GECC 10.97
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.